NetraMark Holdings Inc 最大收入来源是 Biopharmaceutical Products,在最近的收益报告中收入为 512,544,470。就地区而言, China (excluding Hong Kong and Taiwan) 是 NetraMark Holdings Inc 的主要市场,收入为 409,107,819。
NetraMark Holdings Incは収益を上げていますか?
不、最新の財務諸表によると、NetraMark Holdings Incの純损失は$-5です。
NetraMark Holdings Incに負債はありますか?
不、NetraMark Holdings Incの負債は0です。
NetraMark Holdings Incの発行済株式数は何株ですか?
NetraMark Holdings Incの総発行済株式数は87.37株です。
关键数据
前收盘价
$0.593
开盘价
$0.593
当日区间
$0.593 - $0.593
52周范围
$0.593 - $1.26
交易量
500
平均成交量
1.2K
股息收益率
--
每股收益(TTM)
-0.05
市值
$54.4M
什么是 NETRAMARK HLDGS INC.?
NetraMark Holdings, Inc. engages in the development of artificial intelligence and machine learning solutions. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-06-08. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.